

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal653sxs

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 SEP 09 CA/CAPLUS records now contain indexing from 1907 to the  
present  
NEWS 4 AUG 05 New pricing for EUROPAFULL and PCTFULL effective  
August 1, 2003  
NEWS 5 AUG 13 Field Availability (/FA) field enhanced in BEILSTEIN  
NEWS 6 AUG 18 Data available for download as a PDF in RDISCLOSURE  
NEWS 7 AUG 18 Simultaneous left and right truncation added to PASCAL  
NEWS 8 AUG 18 FROSTI and KOSMET enhanced with Simultaneous Left and Right  
Truncation  
NEWS 9 AUG 18 Simultaneous left and right truncation added to ANABSTR  
NEWS 10 SEP 22 DIPPR file reloaded  
NEWS 11 DEC 08 INPADOC: Legal Status data reloaded  
NEWS 12 SEP 29 DISSABS now available on STN  
NEWS 13 OCT 10 PCTFULL: Two new display fields added  
NEWS 14 OCT 21 BIOSIS file reloaded and enhanced  
NEWS 15 OCT 28 BIOSIS file segment of TOXCENTER reloaded and enhanced  
NEWS 16 NOV 24 MSDS-CCOHS file reloaded  
NEWS 17 DEC 08 CABA reloaded with left truncation  
NEWS 18 DEC 08 IMS file names changed  
  
NEWS EXPRESS NOVEMBER 14 CURRENT WINDOWS VERSION IS V6.01c, CURRENT  
MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),  
AND CURRENT DISCOVER FILE IS DATED 23 SEPTEMBER 2003  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 17:37:00 ON 08 DEC 2003

=> File bioscience health medicine meetings pharmacology research toxicology  
FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED  
COST IN U.S. DOLLARS

SINCE FILE TOTAL  
ENTRY SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'ADISCTI' ENTERED AT 17:37:08 ON 08 DEC 2003  
COPYRIGHT (C) 2003 Adis Data Information BV

FILE 'ADISINSIGHT' ENTERED AT 17:37:08 ON 08 DEC 2003  
COPYRIGHT (C) 2003 Adis Data Information BV

FILE 'ADISNEWS' ENTERED AT 17:37:08 ON 08 DEC 2003  
COPYRIGHT (C) 2003 Adis Data Information BV

FILE 'AGRICOLA' ENTERED AT 17:37:08 ON 08 DEC 2003

FILE 'ANABSTR' ENTERED AT 17:37:08 ON 08 DEC 2003  
COPYRIGHT (c) 2003 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'AQUASCI' ENTERED AT 17:37:08 ON 08 DEC 2003  
COPYRIGHT 2003 FAO (On behalf of the ASFA Advisory Board). All rights reserved.

FILE 'BIOBUSINESS' ENTERED AT 17:37:08 ON 08 DEC 2003  
COPYRIGHT (C) 2003 Biological Abstracts, Inc. (BIOSIS)

FILE 'BIOCOMMERCE' ENTERED AT 17:37:08 ON 08 DEC 2003  
COPYRIGHT (C) 2003 BioCommerce Data Ltd. Richmond Surrey, United Kingdom. All rights reserved

FILE 'BIOSIS' ENTERED AT 17:37:08 ON 08 DEC 2003  
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'BIOTECHABS' ENTERED AT 17:37:08 ON 08 DEC 2003  
COPYRIGHT (C) 2003 THOMSON DERWENT AND INSTITUTE FOR SCIENTIFIC INFORMATION

FILE 'BIOTECHDS' ACCESS NOT AUTHORIZED

FILE 'BIOTECHNO' ENTERED AT 17:37:08 ON 08 DEC 2003  
COPYRIGHT (C) 2003 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CABA' ENTERED AT 17:37:08 ON 08 DEC 2003  
COPYRIGHT (C) 2003 CAB INTERNATIONAL (CABI)

FILE 'CANCERLIT' ENTERED AT 17:37:08 ON 08 DEC 2003

FILE 'CAPLUS' ENTERED AT 17:37:08 ON 08 DEC 2003  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CEABA-VTB' ENTERED AT 17:37:08 ON 08 DEC 2003  
COPYRIGHT (c) 2003 DECHEMA eV

FILE 'CEN' ENTERED AT 17:37:08 ON 08 DEC 2003  
COPYRIGHT (C) 2003 American Chemical Society (ACS)

FILE 'CIN' ENTERED AT 17:37:08 ON 08 DEC 2003  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2003 American Chemical Society (ACS)

FILE 'CONFSCI' ENTERED AT 17:37:08 ON 08 DEC 2003  
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'CROPB' ENTERED AT 17:37:08 ON 08 DEC 2003  
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'CROPU' ENTERED AT 17:37:08 ON 08 DEC 2003  
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'DISSABS' ENTERED AT 17:37:08 ON 08 DEC 2003  
COPYRIGHT (C) 2003 ProQuest Information and Learning Company; All Rights Reserved.

FILE 'DDFB' ENTERED AT 17:37:08 ON 08 DEC 2003  
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'DDFU' ENTERED AT 17:37:08 ON 08 DEC 2003  
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'DGENE' ENTERED AT 17:37:08 ON 08 DEC 2003  
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'DRUGB' ACCESS NOT AUTHORIZED

FILE 'DRUGMONOG2' ENTERED AT 17:37:08 ON 08 DEC 2003  
COPYRIGHT (C) 2003 IMSWORLD Publications Ltd

FILE 'IMSDRUGNEWS' ENTERED AT 17:37:08 ON 08 DEC 2003  
COPYRIGHT (C) 2003 IMSWORLD Publications Ltd

FILE 'DRUGU' ACCESS NOT AUTHORIZED

FILE 'IMSRESEARCH' ENTERED AT 17:37:08 ON 08 DEC 2003  
COPYRIGHT (C) 2003 IMSWORLD Publications Ltd

FILE 'EMBAL' ENTERED AT 17:37:08 ON 08 DEC 2003  
COPYRIGHT (C) 2003 Elsevier Inc. All rights reserved.

FILE 'EMBASE' ENTERED AT 17:37:08 ON 08 DEC 2003  
COPYRIGHT (C) 2003 Elsevier Inc. All rights reserved.

FILE 'ESBIOBASE' ENTERED AT 17:37:08 ON 08 DEC 2003  
COPYRIGHT (C) 2003 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'FEDRIP' ENTERED AT 17:37:08 ON 08 DEC 2003

FILE 'FOMAD' ENTERED AT 17:37:08 ON 08 DEC 2003  
COPYRIGHT (C) 2003 Leatherhead Food Research Association

FILE 'FOREGE' ENTERED AT 17:37:08 ON 08 DEC 2003  
COPYRIGHT (C) 2003 Leatherhead Food Research Association

FILE 'FROSTI' ENTERED AT 17:37:08 ON 08 DEC 2003  
COPYRIGHT (C) 2003 Leatherhead Food Research Association

FILE 'FSTA' ENTERED AT 17:37:08 ON 08 DEC 2003  
COPYRIGHT (C) 2003 International Food Information Service

FILE 'GENBANK' ENTERED AT 17:37:08 ON 08 DEC 2003

FILE 'HEALSAFE' ENTERED AT 17:37:08 ON 08 DEC 2003  
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'IFIPAT' ENTERED AT 17:37:08 ON 08 DEC 2003  
COPYRIGHT (C) 2003 IFI CLAIMS(R) Patent Services (IFI)

FILE 'IMSPRODUCT' ENTERED AT 17:37:08 ON 08 DEC 2003  
COPYRIGHT (C) 2003 IMSWORLD Publications Ltd

FILE 'JICST-EPLUS' ENTERED AT 17:37:08 ON 08 DEC 2003

COPYRIGHT (C) 2003 Japan Science and Technology Agency (JST)

FILE 'KOSMET' ENTERED AT 17:37:08 ON 08 DEC 2003  
COPYRIGHT (C) 2003 International Federation of the Societies of Cosmetics Chemists

FILE 'LIFESCI' ENTERED AT 17:37:08 ON 08 DEC 2003  
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'MEDICONF' ENTERED AT 17:37:08 ON 08 DEC 2003  
COPYRIGHT (c) 2003 FAIRBASE Datenbank GmbH, Hannover, Germany

FILE 'MEDLINE' ENTERED AT 17:37:08 ON 08 DEC 2003

FILE 'NIOSH TIC' ENTERED AT 17:37:08 ON 08 DEC 2003  
COPYRIGHT (C) 2003 U.S. Secretary of Commerce on Behalf of the U.S. Government

FILE 'NTIS' ENTERED AT 17:37:08 ON 08 DEC 2003  
Compiled and distributed by the NTIS, U.S. Department of Commerce.  
It contains copyrighted material.  
All rights reserved. (2003)

FILE 'NUTRACEUT' ENTERED AT 17:37:08 ON 08 DEC 2003  
Copyright 2003 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'OCEAN' ENTERED AT 17:37:08 ON 08 DEC 2003  
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'PASCAL' ENTERED AT 17:37:08 ON 08 DEC 2003  
Any reproduction or dissemination in part or in full,  
by means of any process and on any support whatsoever  
is prohibited without the prior written agreement of INIST-CNRS.  
COPYRIGHT (C) 2003 INIST-CNRS. All rights reserved.

FILE 'PCTGEN' ENTERED AT 17:37:08 ON 08 DEC 2003  
COPYRIGHT (C) 2003 WIPO

FILE 'PHAR' ENTERED AT 17:37:08 ON 08 DEC 2003  
COPYRIGHT (C) 2003 PJB Publications Ltd. (PJB)

FILE 'PHARMAML' ENTERED AT 17:37:08 ON 08 DEC 2003  
Copyright 2003 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'PHIC' ENTERED AT 17:37:08 ON 08 DEC 2003  
COPYRIGHT (C) 2003 PJB Publications Ltd. (PJB)

FILE 'PHIN' ENTERED AT 17:37:08 ON 08 DEC 2003  
COPYRIGHT (C) 2003 PJB Publications Ltd. (PJB)

FILE 'PROMT' ENTERED AT 17:37:08 ON 08 DEC 2003  
COPYRIGHT (C) 2003 Gale Group. All rights reserved.

FILE 'RDISCLOSURE' ENTERED AT 17:37:08 ON 08 DEC 2003  
COPYRIGHT (C) 2003 Kenneth Mason Publications Ltd.

FILE 'SCISEARCH' ENTERED AT 17:37:08 ON 08 DEC 2003  
COPYRIGHT 2003 THOMSON ISI

FILE 'SYNTHLINE' ENTERED AT 17:37:08 ON 08 DEC 2003  
COPYRIGHT (C) 2003 Prous Science

FILE 'TOXCENTER' ENTERED AT 17:37:08 ON 08 DEC 2003  
COPYRIGHT (C) 2003 ACS

FILE 'USPATFULL' ENTERED AT 17:37:08 ON 08 DEC 2003  
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 17:37:08 ON 08 DEC 2003  
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'VETB' ENTERED AT 17:37:08 ON 08 DEC 2003  
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'VETU' ENTERED AT 17:37:08 ON 08 DEC 2003  
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'WPIDS' ACCESS NOT AUTHORIZED

FILE 'WPINDEX' ENTERED AT 17:37:08 ON 08 DEC 2003  
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'CBNB' ENTERED AT 17:37:08 ON 08 DEC 2003  
COPYRIGHT (c) 2003 ELSEVIER ENGINEERING INFORMATION, INC.

FILE 'CHEMLIST' ENTERED AT 17:37:08 ON 08 DEC 2003  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2003 American Chemical Society (ACS)

FILE 'CSNB' ENTERED AT 17:37:08 ON 08 DEC 2003  
COPYRIGHT (c) 2003 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'ENERGY' ENTERED AT 17:37:08 ON 08 DEC 2003  
COPYRIGHT (c) 2003 USDOE for the IEA-Energy Technology Data Exchange (ETDE)

FILE 'HSDB' ENTERED AT 17:37:08 ON 08 DEC 2003  
COPYRIGHT (C) 2003 NATIONAL LIBRARY OF MEDICINE

FILE 'INIS' ACCESS NOT AUTHORIZED

FILE 'IPA' ENTERED AT 17:37:08 ON 08 DEC 2003  
COPYRIGHT (C) 2003 American Society of Hospital Pharmacists (ASHP)

FILE 'MSDS-CCOHS' ENTERED AT 17:37:08 ON 08 DEC 2003  
Copyright Notice: Permission to copy is not required for this file

FILE 'MSDS-OHS' ENTERED AT 17:37:08 ON 08 DEC 2003  
COPYRIGHT (C) 2003 MDL INFORMATION SYSTEMS (MDL)

FILE 'NAPRALERT' ENTERED AT 17:37:08 ON 08 DEC 2003  
COPYRIGHT (C) 2003 Board of Trustees of the University of Illinois,  
University of Illinois at Chicago.

FILE 'NLDB' ENTERED AT 17:37:08 ON 08 DEC 2003  
COPYRIGHT (C) 2003 Gale Group. All rights reserved.

FILE 'POLLUAB' ENTERED AT 17:37:08 ON 08 DEC 2003  
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'RTECS' ENTERED AT 17:37:08 ON 08 DEC 2003  
COPYRIGHT (C) 2003 U.S. Secretary of Commerce on Behalf of the U.S. Government (DOC)

FILE 'IMOBILITY' ENTERED AT 17:37:08 ON 08 DEC 2003  
COPYRIGHT (C) 2003 Society of Automotive Engineers, Inc.

FILE 'COMPENDEX' ENTERED AT 17:37:08 ON 08 DEC 2003

Compendex Compilation and Indexing (C) 2003  
Elsevier Engineering Information Inc (EEI). All rights reserved.  
Compendex (R) is a registered Trademark of Elsevier Engineering Information Inc.

FILE 'COMPUAB' ENTERED AT 17:37:08 ON 08 DEC 2003  
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'CONF' ENTERED AT 17:37:08 ON 08 DEC 2003  
COPYRIGHT (c) 2003 FIZ Karlsruhe

FILE 'ELCOM' ENTERED AT 17:37:08 ON 08 DEC 2003  
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'IMSDRUGCONF' ENTERED AT 17:37:08 ON 08 DEC 2003  
COPYRIGHT (C) 2003 IMSWORLD Publications Ltd.

FILE 'PAPERCHEM2' ENTERED AT 17:37:08 ON 08 DEC 2003  
Paperchem2 compilation and indexing (C) 2003  
Elsevier Engineering Information Inc. All rights reserved.

FILE 'SOLIDSTATE' ENTERED AT 17:37:08 ON 08 DEC 2003  
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'BABS' ENTERED AT 17:37:08 ON 08 DEC 2003  
COPYRIGHT (c) 2003 Beilstein-Institut zur Foerderung der Chemischen Wissenschaften  
licensed to Beilstein GmbH and MDL Information Systems GmbH

FILE 'DIOGENES' ENTERED AT 17:37:08 ON 08 DEC 2003  
COPYRIGHT (C) 2003 FOI Services, Inc. (FOI)

FILE 'INVESTEXT' ENTERED AT 17:37:08 ON 08 DEC 2003  
COPYRIGHT (C) 2003 Thomson Financial Services, Inc. (TFS)

FILE 'USAN' ENTERED AT 17:37:08 ON 08 DEC 2003  
COPYRIGHT (C) 2003 U.S. Pharmacopeial Convention, Inc. (USPC)

FILE 'DKF' ENTERED AT 17:37:08 ON 08 DEC 2003  
COPYRIGHT (C) 2003 Dokumentation Kraftfahrwesen e.V., Germany

FILE 'FORIS' ENTERED AT 17:37:08 ON 08 DEC 2003  
COPYRIGHT (C) 2003 Informationszentrum Sozialwissenschaften, Bonn (IZS)

FILE 'FORKAT' ENTERED AT 17:37:08 ON 08 DEC 2003  
COPYRIGHT (C) 2003 Bundesministerium fuer Bildung,  
Wissenschaft, Forschung und Technologie (bmb+f)

FILE 'RUSSCI' ENTERED AT 17:37:08 ON 08 DEC 2003  
COPYRIGHT (C) 2003 Andrigal Ltd.

FILE 'SOLIS' ENTERED AT 17:37:08 ON 08 DEC 2003  
COPYRIGHT (C) 2003 Informationszentrum Sozialwissenschaften, Bonn (IZS)

FILE 'UFORDAT' ENTERED AT 17:37:08 ON 08 DEC 2003  
COPYRIGHT (C) 2003 Umweltbundesamt, D-14191 Berlin (UBA)

FILE 'AQUIRE' ENTERED AT 17:37:08 ON 08 DEC 2003  
COPYRIGHT (C) 2003 US Environmental Protection Agency (EPA)

FILE 'ULIDAT' ENTERED AT 17:37:08 ON 08 DEC 2003  
COPYRIGHT (C) 2003 Umweltbundesamt, D-14191 Berlin (UBA)

=> s (tab1 (3A) tak1)

50 FILES SEARCHED...

L1 331 (TAB1 (3A) TAK1)

=> s l1 and (tak1 (3A) (fragment or peptide or segment or 76 or 303 or N-terminal or N-terminus)

UNMATCHED LEFT PARENTHESIS 'AND (TAK1'

The number of right parentheses in a query must be equal to the number of left parentheses.

=> s l1 and (tak1 (3A) (fragment or peptide or segment or 76 or 303 or N-terminal or N-terminus))

12 FILES SEARCHED...

24 FILES SEARCHED...

38 FILES SEARCHED...

49 FILES SEARCHED...

62 FILES SEARCHED...

67 FILES SEARCHED...

85 FILES SEARCHED...

L2 19 L1 AND (TAK1 (3A) (FRAGMENT OR PEPTIDE OR SEGMENT OR 76 OR 303 OR N-TERMINAL OR N-TERMINUS))

=> duplicate

ENTER REMOVE, IDENTIFY, ONLY, OR (?):remove

ENTER L# LIST OR (END):l2

DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, BIOCOMMERCE, DGENE, DRUGMONOG2, IMSRESEARCH, FEDRIP, FOREGE, GENBANK, IMSPRODUCT, KOSMET, MEDICONF, NUTRACEUT, PCTGEN, PHAR, PHARMAML, RDISCLOSURE, SYNTHLINE, CHEMLIST, HSDB, MSDS-CCOHS, MSDS-OHS, RTECS, CONF, IMSDRUGCONF, DIOGENES, INVESTEXT, USAN, FORIS, FORKAT, UFORDAT, AQUIRE'.

ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE

DUPLICATE PREFERENCE IS 'BIOSIS, CANCERLIT, CAPLUS, DGENE, EMBAL, LIFESCI, MEDLINE, SCISEARCH, USPATFULL, USPAT2, WPINDEX'

KEEP DUPLICATES FROM MORE THAN ONE FILE? Y/(N):n

PROCESSING COMPLETED FOR L2

L3 12 DUPLICATE REMOVE L2 (7 DUPLICATES REMOVED)

=> d l3 1-12 bib ab

L3 ANSWER 1 OF 12 CAPLUS COPYRIGHT 2003 ACS on STN

AN 2003:360779 CAPLUS

DN 138:380400

TI **TAK1-TAB1** fusion protein: a novel constitutively active mitogen-activated protein kinase kinase kinase for use in drug screening

IN Sugita, Naohisa; Sakurai, Hiroaki; Sato, Naoya

PA Tanabe Seiyaku Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 34 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2003135070	A2	20030513	JP 2001-335988	20011101
PRAI	JP 2001-335988		20011101		

AB A fusion protein comprising human transforming growth factor- $\beta$ -activated kinase 1 (**TAK1**) N-terminal MAPKKK domain and human **TAK1** binding protein 1 (**TAB1**) C-terminal **TAK1** activation domain, functional as active mutant **TAK1**, encoding cDNAs, recombinant expression, and use in screening **TAK1** inhibitors, are disclosed. **TAK1** and **TAB1** are connect via a linker peptide. Activation of JNK, p38, or IKK, or induction of cytokine prodn., such as IL-6, IL-1, or TNF, may be assayed for screening. **TAK1** mitogen-activated protein kinase kinase kinase (MAP3K) is activated

by its specific activator, **TAK1**-binding protein 1 (**TAB1**). A constitutively active **TAK1** mutant has not yet been generated due to the indispensable requirement of **TAB1** for **TAK1** kinase activity. In this study, the authors generated a novel constitutively active **TAK1** by fusing its kinase domain to the minimal **TAK1**-activation domain of **TAB1**. Co-immunoprecipitation assay demonstrated that these domains interacted intra-molecularly. The **TAK1-TAB1** fusion protein showed a significant MAP3K activity in vitro and activated c-Jun N-terminal kinase/p38 MAPKs and I $\kappa$ B kinase in vivo, which was followed by increased production of interleukin-6. These results indicate that the fusion protein is useful for characterizing the physiological roles of the **TAK1-TAB1** complex.

L3 ANSWER 2 OF 12 USPTAFULL on STN  
AN 2003:232028 USPTAFULL  
TI Method of screening TGF-beta-inhibiting substances  
IN Ono, Koichiro, Gotenba-shi, JAPAN  
Ohtomo, Toshihiko, Gotenba-shi, JAPAN  
Tsuchiya, Masayuki, Gotenba-shi, JAPAN  
PA CHUGAI SEIYAKU KABUSHIKI KAISHA (non-U.S. corporation)  
PI US 2003162228 A1 20030828  
AI US 2003-384743 A1 20030311 (10)  
RLI Division of Ser. No. US 2002-158895, filed on 3 Jun 2002, GRANTED, Pat. No. US 6551840 Continuation of Ser. No. US 2000-529279, filed on 11 Apr 2000, GRANTED, Pat. No. US 6451617 A 371 of International Ser. No. WO 1998-JP4796, filed on 22 Oct 1998, UNKNOWN  
PRAI JP 1997-290188 19971022  
DT Utility  
FS APPLICATION  
LREP FOLEY AND LARDNER, SUITE 500, 3000 K STREET NW, WASHINGTON, DC, 20007  
CLMN Number of Claims: 36  
ECL Exemplary Claim: 1  
DRWN 12 Drawing Page(s)  
LN.CNT 4117  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB A method for screening substances that inhibit binding between a **TAK1** polypeptide and a **TAB1** polypeptide, which comprises contacting the **TAB1** polypeptide to the **TAK1** polypeptide and a test sample and then detecting or determining the **TAK1** polypeptide that is bound to the **TAB1** polypeptide.

L3 ANSWER 3 OF 12 USPTAFULL on STN  
AN 2003:57486 USPTAFULL  
TI Novel protein TAB2  
IN Matsumoto, Kunihiro, Aichi, JAPAN  
PI US 2003040050 A1 20030227  
AI US 2002-151569 A1 20020520 (10)  
RLI Continuation-in-part of Ser. No. WO 1999-JP6466, filed on 19 Nov 1999, UNKNOWN  
DT Utility  
FS APPLICATION  
LREP JANIS K. FRASER, PH.D., J.D., Fish & Richardson P.C., 225 Franklin Street, Boston, MA, 02110-2804  
CLMN Number of Claims: 62  
ECL Exemplary Claim: 1  
DRWN 7 Drawing Page(s)  
LN.CNT 3179  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB A novel signal transducer TAB2 which acts as an adapter molecule of TRAF6 and TAK1 and mediates the activation of TAK1 in the signal transduction of IL-1 was isolated. TAB2 induced the activation of NF- $\kappa$ B and JNK by IL-1. The signal transduction by IL-1 was inhibited by inhibiting the signal transduction of TAB2 with the use of a dominant negative mutant of TAB2. A compound inhibiting the signal



transduction in TAB2 is useful as an anti-inflammatory drug.

L3 ANSWER 4 OF 12 USPATFULL on STN DUPLICATE 1  
AN 2002:280188 USPATFULL  
TI Method of screening TGF-beta-inhibiting substances  
IN Ono, Koichiro, Gotenba-shi, JAPAN  
Ohtomo, Toshihiko, Gotenba-shi, JAPAN  
Tsuchiya, Masayuki, Gotenba-shi, JAPAN  
PA CHUGAI SEIYAKU KABUSHIKI KAISHA (non-U.S. corporation)  
PI US 2002155624 A1 20021024  
US 6551840 B2 20030422  
AI US 2002-158895 A1 20020603 (10)  
RLI Continuation of Ser. No. US 2000-529279, filed on 11 Apr 2000, PENDING A  
371 of International Ser. No. WO 1998-JP4796, filed on 22 Oct 1998,  
UNKNOWN  
PRAI JP 1997-290188 19971022  
DT Utility  
FS APPLICATION  
LREP FOLEY AND LARDNER, SUITE 500, 3000 K STREET NW, WASHINGTON, DC, 20007  
CLMN Number of Claims: 36  
ECL Exemplary Claim: 1  
DRWN 12 Drawing Page(s)  
LN.CNT 4119  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB A method for screening substances that inhibit binding between a  
TAK1 polypeptide and a TAB1 polypeptide, which  
comprises contacting the TAB1 polypeptide to the TAK1  
polypeptide and a test sample and then detecting or determining the TAK1  
polypeptide that is bound to the TAB1 polypeptide.

L3 ANSWER 5 OF 12 USPATFULL on STN  
AN 2002:221385 USPATFULL  
TI TAB1 protein and DNA coding therefore  
IN Matsumoto, Kunihiro, Nagoya-shi, JAPAN  
Nishida, Eisuke, Kyoto-shi, JAPAN  
PA CHUGAI SEIYAKI KABUSHIKI KAISHA (non-U.S. corporation)  
PI US 2002119525 A1 20020829  
AI US 2002-123427 A1 20020417 (10)  
RLI Division of Ser. No. US 2000-688701, filed on 17 Oct 2000, ABANDONED  
Division of Ser. No. US 1999-406854, filed on 29 Sep 1999, GRANTED, Pat.  
No. US 6140042 Division of Ser. No. US 1996-752891, filed on 20 Nov  
1996, GRANTED, Pat. No. US 5837819  
PRAI JP 1996-300856 19961028  
JP 1996-126282 19960424  
DT Utility  
FS APPLICATION  
LREP Stephen A. Bent, Foley & Lardner, Washington Harbour, Suite 500, 3000 K  
Street, N.W., Washington, DC, 20007-5143  
CLMN Number of Claims: 15  
ECL Exemplary Claim: 1  
DRWN 8 Drawing Page(s)  
LN.CNT 1057  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB TAB1 protein having activity which activates factor TAK1 in the  
TGF-beta. signaling pathway, and having the amino acid sequence shown  
in FIG. 1.

L3 ANSWER 6 OF 12 USPATFULL on STN  
AN 2002:238893 USPATFULL  
TI Method of screening TGF-beta. inhibitory substances  
IN Ono, Koichiro, Gotenba, JAPAN  
Ohtomo, Toshihiko, Gotenba, JAPAN  
Tsuchiya, Masayuki, Gotenba, JAPAN  
PA Chugai Seiyaku Kabushiki Kaisha, Tokyo, JAPAN (non-U.S. corporation)

PI US 6451617 B1 20020917  
 WO 9921010 19990429  
 AI US 2000-529279 20000411 (9)  
 WO 1998-JP4796 19981022  
 20000411 PCT 371 date  
 PRAI JP 1997-290188 19971022  
 DT Utility  
 FS GRANTED  
 EXNAM Primary Examiner: Whisenant, Ethan C.; Assistant Examiner: Lu, Frank W  
 LREP Foley & Lardner  
 CLMN Number of Claims: 50  
 ECL Exemplary Claim: 1  
 DRWN 14 Drawing Figure(s); 12 Drawing Page(s)  
 LN.CNT 4214  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 AB A method for screening substances that inhibit binding between a  
**TAK1** polypeptide and a **TAB1** polypeptide, which  
 comprises contacting the **TAB1** polypeptide to the **TAK1**  
 polypeptide and a test sample and then detecting or determining the **TAK1**  
 polypeptide that is bound to the **TAB1** polypeptide.  
 L3 ANSWER 7 OF 12 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN  
 DUPLICATE 2  
 AN 2001:219578 BIOSIS  
 DN PREV200100219578  
 TI The MAPK kinase kinase TAK1 plays a central role in coupling the  
 interleukin-1 receptor to both transcriptional and RNA-targeted mechanisms  
 of gene regulation.  
 AU Holtmann, Helmut; Enninga, Jost; Kaelble, Solveig; Thiefes, Axel; Doerrie,  
 Anneke; Broemer, Meike; Winzen, Reinhard; Wilhelm, Arno; Ninomiya-Tsuji,  
 Jun; Matsumoto, Kunihiro; Resch, Klaus; Kracht, Michael [Reprint author]  
 CS Institute of Pharmacology, Medical School Hannover, Carl-Neuberg-Strasse  
 1, D-30625, Hannover, Germany  
 Kracht.Michael@MH-Hannover.de  
 SO Journal of Biological Chemistry, (February 2, 2001) Vol. 276, No. 5, pp.  
 3508-3516. print.  
 CODEN: JBCHA3. ISSN: 0021-9258.  
 DT Article  
 LA English  
 ED Entered STN: 9 May 2001  
 Last Updated on STN: 18 Feb 2002  
 AB Mechanisms of fulminant gene induction during an inflammatory response  
 were investigated using expression of the chemoattractant cytokine  
 interleukin-8 (IL-8) as a model. Recently we found that coordinate  
 activation of NF-kappaB and c-Jun N-terminal protein kinase (JNK) is  
 required for strong IL-8 transcription, whereas the p38 MAP kinase (MAPK)  
 pathway stabilizes the IL-8 mRNA. It is unclear how these pathways are  
 coupled to the receptor for IL-1, an important physiological inducer of  
 IL-8. Expression of the MAP kinase kinase kinase (MAPKKK) TAK1 together  
 with its coactivator TAB1 in HeLa cells activated all three pathways and  
 was sufficient to induce IL-8 formation, NF-kappaB + JNK2-mediated  
 transcription from a minimal IL-8 promoter, and p38 MAPK-mediated  
 stabilization of a reporter mRNA containing IL-8-derived regulatory mRNA  
 sequences. Expression of a kinase-inactive mutant of TAK1 largely blocked  
 IL-1-induced transcription and mRNA stabilization, as well as formation of  
 endogenous IL-8. Truncated **TAB1**, lacking the **TAK1**  
 binding domain, or a **TAK1**-derived **peptide** containing a  
**TAK1** autoinhibitory domain were also efficient in inhibition.  
 These data indicate that the previously described three-pathway model of  
 IL-8 induction is operative in response to a physiological stimulus, IL-1,  
 and that the MAPKKK TAK1 couples the IL-1 receptor to both transcriptional  
 and RNA-targeted mechanisms mediated by the three pathways.  
 L3 ANSWER 8 OF 12 USPATFULL on STN

AN 2000:146088 USPATFULL  
 TI TAB1 protein and DNA coding therefore  
 IN Matsuomoto, Kunihiro, Nagoya, Japan  
 Nishida, Eisuke, Kyoto, Japan  
 PA Chugai Seiyaku Kabushiki Kaisha, Tokyo, Japan (non-U.S. corporation)  
 PI US 6140042 20001031  
 AI US 1999-406854 19990929 (9)  
 RLI Division of Ser. No. US 1996-752891, filed on 20 Nov 1996, now patented,  
 Pat. No. US 5837819  
 PRAI JP 1996-126282 19960424  
 JP 1996-300856 19961028  
 DT Utility  
 FS Granted  
 EXNAM Primary Examiner: Schwartzman, Robert A.; Assistant Examiner: McGarry,  
 Sean  
 LREP Foley & Lardner  
 CLMN Number of Claims: 1  
 ECL Exemplary Claim: 1  
 DRWN 9 Drawing Figure(s); 8 Drawing Page(s)  
 LN.CNT 1108  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 AB TAB1 protein having activity which activates factor TAK1 in the  
 TGF-.beta. signaling pathway, and having the amino acid sequence shown  
 in FIG. 1.

L3 ANSWER 9 OF 12 USPATFULL on STN  
 AN 1999:150965 USPATFULL  
 TI Tab1 protein and DNA coding therefor  
 IN Matsuomoto, Kunihiro, Nagoya, Japan  
 Nishida, Eisuke, Kyoto, Japan  
 PA Chugai Seiyaku Kabushiki Kaisha, Tokyo, Japan (non-U.S. corporation)  
 PI US 5989862 19991123  
 AI US 1998-144178 19980831 (9)  
 RLI Division of Ser. No. US 1996-752891, filed on 20 Oct 1996, now patented,  
 Pat. No. US 5837819  
 PRAI JP 1996-126282 19960424  
 JP 1996-300856 19961028  
 DT Utility  
 FS Granted  
 EXNAM Primary Examiner: Degen, Nancy; Assistant Examiner: McGarry, Sean  
 LREP Foley & Lardner  
 CLMN Number of Claims: 24  
 ECL Exemplary Claim: 1  
 DRWN 9 Drawing Figure(s); 8 Drawing Page(s)  
 LN.CNT 1049  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 AB TAB1 protein having activity which activates factor TAK1 in the  
 TGF-.beta. signaling pathway, and having the amino acid sequence shown  
 in FIG. 1.

L3 ANSWER 10 OF 12 WPINDEX COPYRIGHT 2003 THOMSON DERWENT on STN  
 AN 1999-312645 [26] WPINDEX  
 DNN N1999-233498 DNC C1999-092304  
 TI Screening for TGF- beta inhibitory substances, which are useful as drugs  
 for treatment of diseases relating to its disorder.  
 DC B04 D16 S03  
 IN OHTOMO, T; ONO, K; TSUCHIYA, M  
 PA (CHUS) CHUGAI SEIYAKU KK; (CHUS) CHUGAI PHARM CO LTD  
 CYC 83  
 PI WO 9921010 A1 19990429 (199926)\* JA 195p  
 RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL  
 OA PT SD SE SZ UG ZW  
 W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD  
 GE GH GM HR HU ID IL IS JP KE KG KR KZ LC LK LR LS LT LU LV MD MG

MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG  
US UZ VN YU ZW

AU 9896468 A 19990510 (199938)

EP 1043586 A1 20001011 (200052) EN

R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

JP 11523715 X 20010410 (200128)

KR 2001031325 A 20010416 (200163)

US 6451617 B1 20020917 (200264)

AU 752461 B 20020919 (200272)

US 2002155624 A1 20021024 (200273)

US 6551840 B2 20030422 (200330)

US 2003162228 A1 20030828 (200357)

ADT WO 9921010 A1 WO 1998-JP4796 19981022; AU 9896468 A AU 1998-96468  
19981022; EP 1043586 A1 EP 1998-950354 19981022, WO 1998-JP4796 19981022;  
JP 11523715 X WO 1998-JP4796 19981022, JP 1999-523715 19981022; KR  
2001031325 A KR 2000-704319 20000421; US 6451617 B1 WO 1998-JP4796  
19981022, US 2000-529279 20000411; AU 752461 B AU 1998-96468 19981022; US  
2002155624 A1 Cont of WO 1998-JP4796 19981022, Cont of US 2000-529279  
20000411, US 2002-158895 20020603; US 6551840 B2 Cont of WO 1998-JP4796  
19981022, Cont of US 2000-529279 20000411, US 2002-158895 20020603; US  
2003162228 A1 Cont of WO 1998-JP4796 19981022, Cont of US 2000-529279  
20000411, Div ex US 2002-158895 20020603, US 2003-384743 20030311  
FDT AU 9896468 A Based on WO 9921010; EP 1043586 A1 Based on WO 9921010; JP  
11523715 X Based on WO 9921010; US 6451617 B1 Based on WO 9921010; AU  
752461 B Previous Publ. AU 9896468, Based on WO 9921010; US 6551840 B2  
Cont of US 6451617; US 2003162228 A1 Cont of US 6451617, Div ex US 6551840  
PRAI JP 1997-290188 19971022

AB WO 9921010 A UPAB: 20030707

NOVELTY - A method of screening for substances which inhibit the binding  
of **TAK1** polypeptide to **TAB1** polypeptide comprises:

(a) contacting the polypeptide in the presence of a sample; and

(b) detecting the amount of bound polypeptide, in which the sample  
can be pre-mixed with **TAK1** or **TAB1** polypeptide first.

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for  
substances obtained by the screening method.

ACTIVITY - None given.

MECHANISM OF ACTION - TGF- beta signal transmission  
inhibitor/activator; extracellular matrix protein production enhancement  
inhibitor/activator; cell proliferation prevention inhibitor/activator;  
monocyte migration inhibitor/activator; physiological activity induction  
inhibitor/activator; immunosuppression inhibitor/activator; amyloid beta  
protein precipitation inhibitor/activator; TGF- beta inhibitors.

USE - The TGF- beta inhibitory substances can be used in drugs for  
indications e.g. as TGF- beta signal transmission inhibitors or  
activators, or extracellular matrix protein production enhancement  
inhibitors or activators, or cell proliferation prevention inhibitors or  
activators, or monocyte migration inhibitors or activators, or  
physiological activity induction inhibitors or activators, or  
immunosuppression inhibitors or activators, or amyloid beta protein  
precipitation inhibitors or activators, and such substances can also be  
inhibitors of the **TAK1** polypeptide function, particularly kinase activity  
(all claimed).

L3 ANSWER 11 OF 12 USPATFULL on STN

AN 1998:144215 USPATFULL

TI **TAB1** protein

IN Matsuomoto, Kunihiro, Nagoya, Japan

Nishida, Eisuke, Kyoto, Japan

PA Ueno, Naoto, Sapporo, Japan (non-U.S. individual)

PI US 5837819 19981117

AI US 1996-752891 19961120 (8)

PRAI JP 1996-126282 19960424

JP 1996-300856 19961028

DT Utility

FS       Granted  
EXNAM   Primary Examiner: Elliott, George C.; Assistant Examiner: McGarry, Sean  
LREP    Foley & Lardner  
CLMN    Number of Claims: 7  
ECL     Exemplary Claim: 1  
DRWN    9 Drawing Figure(s); 8 Drawing Page(s)  
LN.CNT  910

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB       TAB1 protein having activity which activates factor TAK1 in the  
          TGF-.beta. signaling pathway, and having the amino acid sequence shown  
          in FIG. 1.

L3       ANSWER 12 OF 12   DGENE   COPYRIGHT 2003 THOMSON DERWENT on STN  
AN       AAY09544   peptide       DGENE  
TI       Screening for TGF- beta inhibitory substances, which are useful as drugs  
          for treatment of diseases relating to its disorder  
IN       Ohtomo T; Ono K; Tsuchiya M  
PA       (CHUS)       CHUGAI SEIYAKU KK.  
PI       WO 9921010   A1 19990429                   195p  
AI       WO 1998-JP4796   19981022  
PRAI    JP 1997-290188   19971022  
DT       Patent  
LA       Japanese  
OS       1999-312645 [26]  
DESC    Human **TAK1** 6xHis **peptide**.

AB       A method has been developed for screening for substances which inhibit  
          the binding of **TAK1** polypeptide to **TAB1** polypeptide.  
          The method comprises: (a) contacting the polypeptide in the presence of a  
          sample; and (b) detecting the amount of bound polypeptide, in which the  
          sample can be pre-mixed with **TAK1** or **TAB1** polypeptide  
          first. The transforming growth factor (TGF)-beta inhibitory substances  
          can be used in drugs for indications e.g. as TGF-beta signal transmission  
          inhibitors or activators, or extracellular matrix protein production  
          enhancement inhibitors or activators, or cell proliferation prevention  
          inhibitors or activators, or monocyte migration inhibitors or activators,  
          or physiological activity induction inhibitors or activators, or  
          immunosuppression inhibitors or activators, or amyloid beta protein  
          precipitation inhibitors or activators, and such substances can also be  
          inhibitors of the **TAK1** polypeptide function, particularly kinase  
          activity. The present sequence represents a peptide from an example of  
          the present invention.

=>

<-----User Break----->